NextPlat (NXPL) Long-Term Investments (2022 - 2023)
NextPlat's (NXPL) quarterly Long-Term Investments came in at $4.8 million in Q2 2023, down 7.79% quarter-over-quarter from $5.2 million in Q1 2023.
Powered by 
Analysis
NextPlat (NXPL) Long-Term Investments (2022 - 2023) Analysis & Trends
NextPlat (NXPL) has reported Long-Term Investments for 2 consecutive years, with $4.8 million the latest figure, recorded in Q2 2023.
- On a quarterly basis, Long-Term Investments changed N/A year-over-year to $4.8 million in Q2 2023; TTM through Jun 2023 was $4.8 million, a N/A change from a year earlier, with the FY2022 full-year figure at $5.3 million, changed N/A from the prior year.
- Long-Term Investments was $4.8 million for Q2 2023 at NextPlat, down from $5.2 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $5.3 million in Q4 2022 and troughed at $3.5 million in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | - |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 848.23 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | - |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | - |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | - |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 16.30 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 4.82 Mn |
| Mar 31, 2023 | 5.23 Mn |
| Dec 31, 2022 | 5.26 Mn |
| Sep 30, 2022 | 3.55 Mn |